Efficacy and Safety of Secukinumab Combined With Surgery in Moderate to Severe Hidradenitis Suppurativa: An Open-label Cohort Study in Real Clinical Practice

What this Trial Is About

Researchers are evaluating the effectiveness and safety of combining secukinumab with surgery for treating moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease causing painful abscesses and scarring. The study focuses on real-world clinical practice to provide evidence for doctors managing HS patients who often experience a significant decline in quality of life and may not respond well to traditional treatments or TNF-alpha inhibitors. The treatment involves patients receiving secukinumab along with surgical interventions. This combination is being assessed for patients with moderate to severe HS (Hurley stage II-III) who have already undergone surgery and secukinumab therapy. The study follows an open-label cohort design, collecting data retrospectively from patients treated at a dermatologic surgery department. Participants are monitored for at least one year with complete clinical data available. Researchers will measure outcomes including the Hidradenitis Suppurativa Clinical Response (HiSCR) at week 52, changes in inflammatory nodules, abscesses, sinus tracts, pain levels, inflammatory markers, quality of life, work productivity, and adverse effects. This comprehensive follow-up aims to assess how well this combination therapy works and its safety in managing HS over time.

Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa